Five-year resting-state EEG biomarker stability probed in healthy adults

A five-year longitudinal study published in Frontiers has examined whether candidate resting-state electroencephalography (EEG, the recording of scalp electrical potentials) biomarkers in healthy adults remain stable over time and across recording conditions. The work probes state sensitivity — how measurements shift between eyes-open and eyes-closed resting sessions — and the longitudinal reliability of those measurements across a half-decade.

The paper frames its findings around a question central to clinical EEG translation: whether metrics captured once, in a single sitting, can serve as reproducible biomarkers in monitoring units, outpatient EEG labs, or research settings. Five years of follow-up in healthy controls provides the long-horizon data most EEG biomarker studies lack.

Resting-state EEG, recorded at the scalp with the subject quietly alert, generates quantitative metrics that researchers increasingly consider as candidates for depression, attention-deficit disorder, and neurodegeneration. Common candidates include spectral power in standard frequency bands (delta below 4 Hz, theta 4–8 Hz, alpha 8–13 Hz, beta 13–30 Hz, gamma above 30 Hz), individual alpha peak frequency, and microstate parameters (short-lived quasi-stable scalp topography patterns).

The combination tested in the Frontiers article addresses two threats to biomarker validity at once. Short-term variability driven by mental state during recording threatens reproducibility. Longer-term drift from aging, electrode-paste chemistry, or hardware changes threatens longitudinal comparison. A measure stable under both stressors carries more weight in clinical decision-making.

What does this change for neurophysiology labs?

The dataset offers a calibration reference for adult controls that other research groups can compare against their own candidate biomarkers. For reading rooms interpreting quantitative EEG reports, it underscores that numerical values carry protocol-specific assumptions that practitioners should verify before clinical use.

How might the findings translate to patient populations?

The paper restricts its cohort to healthy adults, positioning the stability data as a baseline against which patient data can later be benchmarked. Generalization to epilepsy, dementia, or psychiatric cohorts remains untested here.

Methodologically, longitudinal EEG stability work relies on consistent electrode placement, standardized montages (defined scalp electrode arrangements), and matched recording epochs across visits. A five-year window implies hardware turnover at least once, as well as subject retention challenges, both of which constrain the dataset.

For neurophysiologists building biomarker validation pipelines, the takeaway is direct: any resting-state metric proposed for clinical use should pass both a state-sensitivity check and a multi-year stability test before it enters decision pathways. The healthy-adult baseline established in this Frontiers paper offers one such reference point.

Multicenter replication and parallel testing in patient groups will determine whether the stability patterns documented here hold across recording hardware, populations, and clinical settings.